Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) was up 6.6% during mid-day trading on Wednesday . The company traded as high as $35.65 and last traded at $34.89, with a volume of 2,030,878 shares. The stock had previously closed at $32.74.

A number of equities research analysts recently issued reports on ACAD shares. Cowen and Company reissued a “buy” rating on shares of Acadia Pharmaceuticals in a research report on Sunday, April 17th. Aegis reissued a “buy” rating and set a $54.00 price target on shares of Acadia Pharmaceuticals in a research report on Friday, April 1st. Needham & Company LLC reissued a “buy” rating and set a $49.00 price target on shares of Acadia Pharmaceuticals in a research report on Thursday, March 31st. JPMorgan Chase & Co. reissued a “buy” rating on shares of Acadia Pharmaceuticals in a research report on Monday, March 28th. Finally, Piper Jaffray Cos. reissued a “buy” rating and set a $44.00 price target (up previously from $39.00) on shares of Acadia Pharmaceuticals in a research report on Sunday, March 27th. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Acadia Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $46.20.

The firm’s market cap is $4.08 billion. The firm’s 50 day moving average price is $35.34 and its 200 day moving average price is $28.39.

Acadia Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.03. During the same period in the previous year, the firm posted ($0.40) earnings per share. On average, analysts expect that Acadia Pharmaceuticals Inc. will post ($1.81) earnings per share for the current year.

In related news, EVP Glenn Baity sold 4,057 shares of Acadia Pharmaceuticals stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $35.00, for a total value of $141,995.00. Following the sale, the executive vice president now owns 66,978 shares of the company’s stock, valued at approximately $2,344,230. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

A number of large investors have modified their holdings of the stock. Dimensional Fund Advisors LP boosted its stake in shares of Acadia Pharmaceuticals by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 150,666 shares of the biopharmaceutical company’s stock worth $5,372,000 after buying an additional 1,739 shares during the last quarter. Morgan Stanley boosted its stake in shares of Acadia Pharmaceuticals by 9.3% in the fourth quarter. Morgan Stanley now owns 321,183 shares of the biopharmaceutical company’s stock worth $11,449,000 after buying an additional 27,260 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of Acadia Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 77,957 shares of the biopharmaceutical company’s stock worth $2,779,000 after buying an additional 466 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Acadia Pharmaceuticals by 13.6% in the fourth quarter. New York State Common Retirement Fund now owns 95,020 shares of the biopharmaceutical company’s stock worth $3,387,000 after buying an additional 11,400 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Acadia Pharmaceuticals by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 194,000 shares of the biopharmaceutical company’s stock worth $6,916,000 after buying an additional 900 shares during the last quarter.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, Schizophrenia and Sleep disturbances.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.